Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Book value per share
Regeneron Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 299×, up 9.84% from 272× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 329×. Over the past ten years it has ranged from 35.5× (fiscal 2015) to 299× (fiscal 2025) — the current reading is the highest in ten years. Regeneron Pharmaceuticals, Inc. ranks 3rd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 299× | 9.84% |
| FY2024 | 272× | 11.76% |
| FY2023 | 243× | 15.03% |
| FY2022 | 212× | 19.18% |
| FY2021 | 178× | 73.29% |
| FY2020 | 102× | 0.90% |
| FY2019 | 102× | 25.13% |
| FY2018 | 81.2× | 40.42% |
| FY2017 | 57.8× | 36.01% |
| FY2016 | 42.5× | 19.83% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 329× | 6.78% |
| Jun 2026 | 308× | 2.09% |
| Mar 2026 | 302× | 1.11% |
| Dec 2025 | 299× | 0.00% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 329× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 82.5× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| MRNA Moderna, Inc. compare | 17.0× |
| RVMD Revolution Medicines, Inc. compare | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement